glp-1 and liver Multiple target tissue effects of analogues on non-alcoholic fatty disease (NAFLD) non-alcoholic steatohepatitis (NASH) Therapeutic Mechanisms and Clinical Effects

Digestion 74(2):7884 Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V et al (2004) One weeks treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes

Balogh, D., Hackl, J

W.ZharikovA.BorahA.et al (2016)

The approval was supported by results from the SURMOUNT-OSA trial that revealed Zepbound led to a significant reduction in the apnea-hypopnea index at 52 weeks compared to placebo in individuals who were and were not receiving PAP therapy